Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene

INTERVENTION: Observation group:Methotrexate + folic acid tablets + Adamumab + Wenyang Tongluo Recipient;Primary untreated group:No treatment was given, only blood was drawn before treatment, and follow‐up treatment was not considered in this group. Patients were advised to seek medical treatment by themselves and follow the doctor's advice;Therapeutic effective group:Continue with the original regimen;The control group:Methotrexate + folic acid tablets + adamulizumab + simulation agent;The normal group:No special treatment will be given; CONDITION: Rheumatoid arthritis PRIMARY OUTCOME: TCM syndrome scores;MRNA and protein expression levels of p‐glycoprotein;DAS28;Therapeutic Effect of TCM Diseases;Protein mRNA and protein expression levels in breast cancer; SECONDARY OUTCOME: Number of joint tenderness;Patients were assessed for overall disease status VAS score;Anti‐cyclic citrullinate peptide antibody;Blood sedimentation;Rheumatoid factor;Joint swelling number;C‐reactive protein;The overall disease status VAS score was assessed by the investigator;Patients were assessed by VAS scale of pain; INCLUSION CRITERIA: 1 The normal group (1) Age between 18 and 70, gender is not limited; (2) Deny the history of rheumatoid arthritis and immune diseases; (3) No relevant history of serious, acute or chronic diseases; (4) Informed consent, voluntary subjects. 2 Untreated group (1) It conforms to the Western medical diagnostic criteria of RA and the Chinese medical diagnostic criteria of Fengcold‐dampness‐Bi syndrome; (2) Age between 18 and 70, gender is not limited; (3) First diagnosis, no use of anti‐RA drug therapy; (4) The disease was active, DAS28 > 2.6. 3 Treatment effective group (1) It conforms to the western medical diagnostic criteria of RA, the effective treatment criteria of ACR20 in 1995, and the traditional Chinese medical diagnostic criteria of Fengcold‐dampness‐Bi syndrome; (2) Age 18 70 years old, gender is not limited; (3) DMARDS‐based drug treatment for more than half a year, no use of biological agents and hormone